Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YH 002

Next Previous
Drug Profile

YH 002

Alternative Names: YH-002

Latest Information Update: 15 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eucure Biopharma
  • Developer Beijing Biocytogen; Eucure Biopharma; Syncromune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; OX40 receptor agonists; Regulatory T-lymphocyte inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 15 Sep 2023 YH 002 is still in phase I trial for Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV) (Beijing Biocytogen pipeline, September 2023)
  • 15 Sep 2023 Preclinical trials in Cancer (Intratumoural) (Beijing Biocytogen pipeline, September 2023)
  • 04 Jul 2023 Eucure (Beijing) Biopharma completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in China and Australia (IV) (NCT05169697)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top